Antioxidants as therapy for Parkinson's disease

Antioxidants and Redox Signaling

Volumn 7, Issue 5-6, 2005, Pages 694-700

  Shults, Clifford W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 8 HYDROXY 2 DEOXYGUANOSINE; 8 HYDROXYGUANINE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ANTIOXIDANT; CLIOQUINOL; DEOXYGUANOSINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; IRON CHELATE; LEVODOPA; MELATONIN; NITRIC OXIDE; NITRONE; OXIDOPAMINE; PEROXYNITRITE; POLYPHENOL; PRAMIPEXOLE; REACTIVE OXYGEN METABOLITE; ROPINIROLE; SELEGILINE; SUPEROXIDE DISMUTASE; UBIQUINONE; UNCLASSIFIED DRUG;

BERRY; CLINICAL TRIAL; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG EFFECT; HUMAN; LEWY BODY; LIPID OXIDATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NITRATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TEA;

ANIMALS; ANTIOXIDANTS; BRAIN; HUMANS; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES;

EID: 17644421395     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.694     Document Type: Review

References (75)

1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, and Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69: 1326-1329, 1997.
2. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, and Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-2003, 1997.
3. Anderson DW, Neavin T, Smith JA, and Schneider JS. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 905: 44-53, 2001.
4. Antolin I, Mayo JC, Sainz RM, del Brio M de L, Herrera F, Martin V, and Rodriguez C. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 943: 163-173, 2002.
5. 10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783: 109-114, 1998.
6. Becker DA. Diagnostic and therapeutic applications of azulenyl nitrone spin traps. Cell Mol Life 56: 626-633, 1999.
7. Beckman JS. Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann N Y Acad Sci 738: 69-75, 1994.
8. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 56: 317-333, 1998.
9. Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, and Stoessl AJ. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184(Suppl 1): S68-S79, 2003.
10. Cadet JL, Katz M, Jackson-Lewis V, and Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476: 10-15, 1989.
11. Cassarino DS, Fall CP, Smith TS, and Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71: 295-301, 1998.
12. Checkoway H, Powers K, Smith-Weiler T, Franklin GM, Longstreth WT Jr, and Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 155: 732-738, 2002.
13. Choi JY, Park CS, Kim DJ, Cho MH, Jin BK, Pie JE, and Chung WG. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 23: 367-374, 2002.
14. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, and Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209-210, 1984.
15. Dabbeni-Sala F, Di Santo S, Franceschini D, Skaper SD, and Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex 1 activity. FASEB J 15: 164-170 2001.
16. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, and Milzani A, Protein carbonylation in human diseases, Trends Mol Med 9: 169-176, 2003.
17. de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, van der Meché FG, and Hofman A. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 54: 762-765, 1997.
18. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, and Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389, 1989.
19. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, and Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4): 1953-1975, 1991.
20. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, and Marsden CD. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9: 92-97, 1994. Erratum in: Mov Disord 9: 380, 1994.
21. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, and Marsden CD. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9: 92-97, 1994. Erratum in: Mov Disord 9: 380, 1994.
22. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32 Suppl: S128-S132, 1992.
23. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, and Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 90: 985-989, 2000.
24. Golbe LI, Farrell TM, and Davis PH. Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol 45: 1350-1353, 1988.
25. Goldstein S and Lestage P. Chemical and pharmacological aspects of heteroaryl-nitrones. Curr Med Chem 7: 1255-1267, 2000.
26. Grünblatt E, Mandel S, Gassen M, and Youdim MB. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J Neural Transm Suppl 55: 57-70, 1999.
27. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716, 2001.
28. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33: 774-797, 2002.
29. Heikkila RE, Hess A, and Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. Life Sci 36: 231-236, 1985.
30. Horvath TL, Diano S, Leranth C, Garcia-Segura LM, Cowley MA, Shanabrough M, Elsworth JD, Sotonyi P, Roth RH, Dietrich EH, Matthews RT, Barnstable CJ, and Redmond DE Jr. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology 144(Suppl 7): 2757-2760, 2003.
31. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, and Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838: 51-59, 1999.
32. Ingold KU, Webb AC, Witter D, Burton GW, Metcalfe TA, and Muller DP. Vitamin E remains the major lipid-soluble, chain-breaking antioxidant in human plasma even in individuals suffering severe vitamin E deficiency. Arch Biochem Biophys 259: 224-225, 1987.
33. Ischiropoulos H and Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 111: 163-169, 2003.
34. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3: S26-S36; discussion S36-S38, 2003.
35. Jiménez-Jiménez FJ, Molina JA, de Bustos F, Garcia-Redondo A, Gómez-Escalonilla C, Martinez-Salio A, Berbel A, Camacho A, Zurdo M, Barcenilla B, Enríquez de Salamanca R, and Arenas J. Serum levels of coenzyme Q10 in patients with Parkinson's disease. J Neurol Transm 107: 177-181, 2000.
36. +) neurotoxicity in rats. Neurosci Lett 245: 61-64, 1998.
37. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, and Andersen JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909, 2003.
38. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, and Itoyama Y. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 9: 244-248, 2002.
39. Klivenyi P, Matthews RT, Wermer M, Yang L, MacGarvey U, Becker DA, Natero R, and Beal MF. Azulenyl nitrone spin traps protect against MPTP neurotoxicity. Exp Neurol 152: 163-166, 1998.
40. Lass A and Sohal RS. Electron transport-linked ubiquinone-dependent recycling of α-tocopherol inhibits autooxidation of mitochondrial membranes. Arch Biochem Biophys 352: 229-236, 1998.
41. Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, Huang S, and Matzuk MM. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 93: 9782-9787, 1996.
42. Levites Y, Weinreb O, Maor G, Youdim MB, and Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78: 1073-1082, 2001.
43. Lewén A, Matz P, and Chan PH. Free radical pathways in CNS injury. J Neurotrauma 17: 871-890, 2000.
44. Li XJ, Gu J, Lu SD, and Sun FY. Melatonin attenuates MPTP-induced dopaminergic neuronal injury associated with scavenging hydroxyl radical. J Pineal Res 32: 47-52, 2002.
45. Mandel S, Weinreb O, Amit T, and Youdim MB. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3- gallate: implications for neurodegenerative diseases. J Neurochem 88: 1555-1569, 2004.
46. Martinovits G, Melamed E, Cohen O, Rosenthal J, and Uzzan A. Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Neurosci Lett 69: 192-197, 1986.
47. Matsubara T, Azuma T, Yoshida S, and Yamagami T. Serum coenzyme Q-10 level in Parkinson syndrome. In: Biomedical and Clinical Aspects of Coenzyme Q, edited by Folkers K, Littarru GP, and Yamagami, T. Amsterdam: Elsevier Science Publishers, 1991, pp. 159-166.
48. Matthews RT, Klivenyi P, Mueller G, Yang L, Wermer M, Thomas CE, and Beal MF. Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Exp Neurol 57: 120-126, 1999.
49. Mihatsch W, Russ H, Gerlach M, Riederer P, and Przuntek H. Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations. J Neural Transm Park Dis Dement Sect 3: 73-78, 1991.
50. Molina JA, de Bustos F, Ortiz S, Del Ser T, Seijo M, Benito-Léon J, Oliva JM, Pérez S, and Manzanares J. Serum levels of coenzyme Q in patients with Lewy body disease. J Neural Transm 109: 1195-1201, 2002.
51. Morgan WW and Nelson JF. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res 921: 115-121, 2001.
52. Moussaoui S, Obinu MC, Daniel N, Reibaud M, Blanchard V, and Imperato A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp Neurol 166: 235-245, 2000.
53. Muralikrishnan D and Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12: 905-912, 1998.
54. Nie G, Cao Y, and Zhao B. Protective effects of green tea polyphenols and their major component, (-)-epigallocatechin-3-gallate (EGCG), on 6-hydroxydopamine-induced apoptosis in PC12 cells. Redox Rep 7: 171-177, 2002.
55. Pappert EJ, Tangney CC, Goetz CG, Ling ZD, Lipton JW, Stebbins GT, and Carvey PM. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology 47: 1037-1042, 1996.
56. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183, 1993.
57. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653-1661, 2002.
58. Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, and Wall RA. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 60: 109-114, 1985.
59. Perry TL, Yong VW, Hansen S, Jones K, Bergeron C, Foulks JG, and Wright JM. Alpha-tocopherol and betacarotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurol Sci 81:321-331, 1987.
60. Reiter RJ, Carneiro RC, and Oh CS. Melatonin in relation to cellular antioxidative defense mechanisms. Horm Metab Res 29: 363-372, 1997.
61. Roghani M and Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res 892: 211-217, 2001.
62. Sanchez-Ramos JR, Overvil E, and Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3: 197-204, 1994.
63. Scheider WL, Hershey LA, Vena JE, Holmlund T, Marshall JR, and Freudenheim JL. Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov Disord 12: 190-196, 1997.
64. Schulz JB, Henshaw DR, Matthews RT, and Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol 132: 279-283, 1995.
65. Shachar DB, Kahana N, Kampel V, Warshawsky A, and Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46: 254-263, 2004.
66. Shaw KM, Stern GM, and Sandler M. Melatonin and parkinsonism. Lancet 1: 271, 1973.
67. 10 in neurodegenerative diseases. Curr Med Chem 10: 1917-1921, 2003.
68. 10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42: 261-264, 1997.
69. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M, and the Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550, 2002.
70. Vatassery GT, Fahn S, and Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 50: 1900-1902, 1998.
71. Vatassery GT, Bauer T, and Dysken M. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. Am J Clin Nutr 70: 793-801, 1999.
72. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, and Brooks DJ. REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54: 93-101, 2003.
73. Willis GL and Armstrong SM. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol Behav 66: 785-795, 1999.
74. Yoshioka M, Tanaka K, Miyazaki I, Fujita N, Higashi Y, Asanuma M, and Ogawa N. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res 43: 259-267, 2002.
75. Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, and Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59: 1161-1169, 2002.